Results 41 to 50 of about 416,036 (340)

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Antioxidants, 2020
Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer ...
Wenyu Wang, Jihye Im, Soochi Kim, Suin Jang, Youngjin Han, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran, Yong Sang Song   +8 more
doaj   +1 more source

Nucleosomes and Cisplatin

Chemistry & Biology, 2010
In order to form a covalent complex with DNA inside human cells, cisplatin has to overcome the protective environment of a nucleosome, where DNA is complexed with histone proteins. Todd and Lippard (2010) expand our understanding of this process by describing the structure of a nucleosome containing a Pt-DNA adduct, which has important implications for
openaire   +3 more sources

Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicin [PDF]

Cancer, 1985
Responses and toxicity after treatment with cisplatin and cisplatin-doxorubicin were compared in two groups of patients with unresectable or metastatic osteosarcoma. Complete or partial responses developed in 3 of 18 individuals treated with cisplatin, and in 5 of 19 after the two-drug combination.
Charles B. Pratt, John Champion, Bhaskar N. Rao, Neil Senzer, Edwin C. Douglass, Debbie Bowles Crom, William E. Meyer, Alexander A. Green   +7 more
openaire   +3 more sources

Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design [PDF]

, 2009
The main task of the medicinal chemist is to design molecules that interact specifically with derailed or degenerating processes in a diseased organism, translating the available knowledge of pathobiochemical and physiological data into chemically ...
Bruijnincx, Pieter C. A., Sadler, P. J.
core   +1 more source

Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. [PDF]

PLoS ONE, 2011
Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable physicochemical characteristics and severe side effects.
Lihua Cheng, Chengmeng Jin, Wen Lv, Qiuping Ding, Xu Han   +4 more
doaj   +1 more source

European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. [PDF]

, 2019
Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s) are unclear and there ...
Abedi, Sina, Atilano, Shari R, Bota, Daniela, Chang, Steven, Chwa, Marilyn, Jazwinski, S Michal, Kenney, M Cristina, Liu, Catherine, Lu, Stephanie, Miceli, Michael V, Norman, Lucas, Patel, Tej H, Thaker, Kunal, Udar, Nitin   +13 more
core   +1 more source

MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex. [PDF]

, 2015
MCM8-9 complex is required for homologous recombination (HR)-mediated repair of double-strand breaks (DSBs). Here we report that MCM8-9 is required for DNA resection by MRN (MRE11-RAD50-NBS1) at DSBs to generate ssDNA.
Dutta, Anindya, Handa, Naofumi, Im, Jun-Sub, Kowalczykowski, Stephen C, Lee, Kyung Yong, Park, Jonghoon, Shibata, Etsuko   +6 more
core   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer [PDF]

, 2010
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Fujimoto, Nobukazu, Fujiwara, Yoshiro, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Tanimoto, Mitsune, Toyooka, Shinichi, Ueoka, Hiroshi, Umemura, Shigeki   +8 more
core   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source